查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1901619

卵巢癌药物市场－全球产业规模、份额、趋势、机会和预测，按药物类别、肿瘤类型、配销通路、地区和竞争格局划分，2021-2031年预测

Ovarian Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Tumor Type, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球卵巢癌药物市场规模预计将从2025年的43.2亿美元成长至2031年的63.6亿美元，复合年增长率（CAGR）为6.66%。卵巢癌药物涵盖多种药理干预措施，包括铂类化疗药物、聚（ADP-核糖）聚合酶（PARP）抑制剂和血管生成抑制剂，旨在治疗卵巢、输卵管和腹膜的恶性肿瘤。该市场的主要驱动力是全球卵巢癌发生率的上升以及老年人口的增长，因为年龄是该疾病的重要风险因素。

市场概览
预测期 2027-2031
市场规模：2025年 43.2亿美元
市场规模：2031年 63.6亿美元
复合年增长率：2026-2031年 6.66%
成长最快的细分市场 烷基化剂
最大的市场 北美洲

主要市场驱动因素

PARP抑制剂和标靶疗法的进步正在从根本上改变卵巢癌的临床治疗，它们具有更精准的作用机制，与传统化疗相比能够显着改善患者的预后。市场正经历着向抗体药物偶联物和维持疗法的重大转变，这些药物和疗法针对特定的生物标记物，例如叶酸受体α。

主要市场挑战

新型标靶疗法和免疫疗法的高昂费用严重阻碍了全球卵巢癌药物市场的成长。这些先进疗法的高定价结构造成了巨大的经济负担，迫使医疗保险机构实施严格的报销政策，而这些政策往往将患者资格限制在一小部分人群中。

主要市场趋势

针对铂类抗药性疾病的新疗法研发正日益关注不同的组织学亚型，而非将抗药性病例视为一个整体进行治疗。低度浆液性卵巢癌（LGSOC）标靶抑制剂的出现便是这一趋势的例证。 LGSOC是一种罕见且对化疗抗药性的疾病，其致病机制与RAS/MAPK路径密切相关。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球卵巢癌药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依肿瘤类型（上皮性卵巢癌、卵巢低度恶性潜能肿瘤、生殖细胞肿瘤、性索间质肿瘤）
    • 按配销通路（医院药房、零售药房、网路药房）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美卵巢癌药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第七章：欧洲卵巢癌药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区卵巢癌药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲卵巢癌药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东和非洲：国家分析
    • 沙乌地阿拉伯
    • 阿联酋
    • 南非

第十章：南美洲卵巢癌药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章：市场动态

  • 司机
  • 挑战

第十二章：市场趋势与发展

  • 併购
  • 产品发布
  • 最新进展

第十三章：全球卵巢癌药物市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商议价能力
  • 顾客的力量
  • 替代产品的威胁

第十五章：竞争格局

  • AstraZeneca, Plc
  • GlaxoSmithKline, Plc
  • Merck & Co.
  • Clovis Oncology, Inc.
  • F. Hoffmann-La Roche AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Company
  • Amgen Inc.
  • CH Boehringer Sohn Ko. KG
  • Novartis AG

第十六章：策略建议

第17章调查会社について・免责事项

简介目录
Product Code: 12865

The Global Ovarian Cancer Drugs Market will grow from USD 4.32 Billion in 2025 to USD 6.36 Billion by 2031 at a 6.66% CAGR. Ovarian cancer drugs encompass a diverse range of pharmacological interventions, including platinum-based chemotherapies, poly (ADP-ribose) polymerase (PARP) inhibitors, and angiogenesis inhibitors, designed to treat malignancies of the ovaries, fallopian tubes, and peritoneum. The market is primarily driven by the increasing global incidence of ovarian cancer and the growing geriatric population, as age constitutes a significant risk factor for the disease.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.32 Billion
Market Size 2031USD 6.36 Billion
CAGR 2026-20316.66%
Fastest Growing SegmentAlkylating Agents
Largest MarketNorth America

Key Market Drivers

Advancements in PARP inhibitors and targeted therapeutics are fundamentally altering the clinical management of ovarian cancer by offering precise mechanisms of action that improve patient outcomes compared to traditional chemotherapy. The market is witnessing a significant shift towards antibody drug conjugates and maintenance therapies that target specific biomarkers like folate receptor alpha. This transition is exemplified by the commercial success of recently approved agents which are rapidly capturing market share.

Key Market Challenges

The prohibitive cost associated with novel targeted therapies and immunotherapies constitutes a substantial impediment to the growth of the global ovarian cancer drugs market. High pricing structures for these advanced regimens lead to significant financial toxicity, forcing healthcare payers to implement stringent reimbursement policies that often restrict patient eligibility to a narrow subset of the population. In many regions, particularly developing economies, the resulting high out-of-pocket expenses effectively place these life-extending treatments out of reach for many individuals.

Key Market Trends

The development of novel therapies for platinum-resistant disease is increasingly focusing on distinct histological subtypes rather than treating resistant cases as a monolithic group. This trend is exemplified by the emergence of targeted inhibitors for low-grade serous ovarian cancer (LGSOC), a rare and chemo-resistant form of the disease driven by the RAS/MAPK pathway. Unlike broad-spectrum chemotherapy or antibody-drug conjugates, these regimens utilize RAF/MEK clamps to disrupt oncogenic signaling in tumors harboring KRAS mutations.

Key Market Players

  • AstraZeneca, Plc
  • GlaxoSmithKline, Plc
  • Merck & Co.
  • Clovis Oncology, Inc.
  • F. Hoffmann-La Roche AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Company
  • Amgen Inc.
  • C.H. Boehringer Sohn Ko. KG
  • Novartis AG

Report Scope:

In this report, the Global Ovarian Cancer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Ovarian Cancer Drugs Market, By Tumor Type:

  • Epithelial Ovarian Cancer
  • Ovarian Low Malignant Potential Tumor
  • Germ Cell Tumor
  • Sex Cord-Stromal Tumor

Ovarian Cancer Drugs Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Ovarian Cancer Drugs Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Ovarian Cancer Drugs Market.

Available Customizations:

Global Ovarian Cancer Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Ovarian Cancer Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Tumor Type (Epithelial Ovarian Cancer, Ovarian Low Malignant Potential Tumor, Germ Cell Tumor, Sex Cord-Stromal Tumor)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Ovarian Cancer Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Tumor Type
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Ovarian Cancer Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Tumor Type
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Ovarian Cancer Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Tumor Type
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Ovarian Cancer Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Tumor Type
        • 6.3.3.2.2. By Distribution Channel

7. Europe Ovarian Cancer Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Tumor Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Ovarian Cancer Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Tumor Type
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Ovarian Cancer Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Tumor Type
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Ovarian Cancer Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Tumor Type
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Ovarian Cancer Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Tumor Type
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Ovarian Cancer Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Tumor Type
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Ovarian Cancer Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Tumor Type
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Ovarian Cancer Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Tumor Type
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Ovarian Cancer Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Tumor Type
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Ovarian Cancer Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Tumor Type
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Ovarian Cancer Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Tumor Type
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Ovarian Cancer Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Tumor Type
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Ovarian Cancer Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Tumor Type
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Ovarian Cancer Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Tumor Type
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Ovarian Cancer Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Tumor Type
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Ovarian Cancer Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Tumor Type
        • 9.3.3.2.2. By Distribution Channel

10. South America Ovarian Cancer Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Tumor Type
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Ovarian Cancer Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Tumor Type
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Ovarian Cancer Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Tumor Type
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Ovarian Cancer Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Tumor Type
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Ovarian Cancer Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AstraZeneca, Plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. GlaxoSmithKline, Plc
  • 15.3. Merck & Co.
  • 15.4. Clovis Oncology, Inc.
  • 15.5. F. Hoffmann-La Roche AG
  • 15.6. Bristol-Myers Squibb Co.
  • 15.7. Eli Lilly and Company
  • 15.8. Amgen Inc.
  • 15.9. C.H. Boehringer Sohn Ko. KG
  • 15.10. Novartis AG

16. Strategic Recommendations

17. About Us & Disclaimer